Calton & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Calton & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-285	Closed	-$8K	–	349
2017 Q4	$8K	Buy	+285	New	+$9.11K	﹤0.01%	1113

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Calton & Associates's ACAD Position: Q1 2018 in Review

Calton & Associates sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 285 shares — an estimated $8K sold.

Calton & Associates first reported a position in ACAD in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

Calton & Associates reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 285 Acadia Pharmaceuticals shares in Q1 2018, an estimated $8K.
Calton & Associates first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Calton & Associates's Acadia Pharmaceuticals position peaked at $8K in Q4 2017.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.